Text Size

Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan

Miki A., Miyamoto E., Ishida N., Shii D., Hori K., LESPOIR Research Group

  • 2022
  • Advances in Therapy
View publication
  • Therapeutic Area


  • Categories

    Post-Approval studies/RWE

  • Affiliations

    Department of Ophthalmology, Osaka University Graduate School of Medicine, Yamadaoka, Suita, Osaka 2-15, Japan; Department of Innovative Visual Science, Osaka University Graduate School of MedicineOsaka, Japan; Japan Medical Affairs Group, Santen Pharmaceutical Co., Ltd.Osaka, Japan

Related Publications

Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: 2-year Results from a Randomized, Multicenter Study

Panarelli JF, Moster MR, Garcia-Feijoo J, Flowers BE, Baker ND, Barnebey HS, Grover DS, Khatana AK, Lee B, Nguyen T, Stiles MC, Sadruddin O, Khaw PT.

Omidenepag Isopropyl in Latanoprost Low/Non-Responders with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3, Non-Randomized, Two-Phase, Open-Label Study

Panarelli JF, Bowden EC, Tepedino ME, Odani-Kawabata N, Pei Z, McLaurin EB, Ropo A.

The Development of a SIBS Shunt to Treat Glaucoma

Pinchuk L.

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022